TBTomislav Bečejac

Tomislav Bečejac

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomislav Bečejac has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Challenges in managing tracheal adenoid cystic carcinoma of the proximal trachea complicated by COVID-19 and bilateral vocal cord palsy

    by Nikolina Tutić, Tomislav Bečejac, Klara Brekalo, Mihovil Penavić, Maja Cvitanović, Sara Burić, Helen Marie Chiddenton, Ivan Erić, Katarina Sabol

  • Open Access

    Malignant melanoma identified within a pulmonary sequestration- a case report

    by Tomislav Bečejac, Mihovil Penavić, Marko Vrančić, Ivan Bunjevac, Ana Mataić, Andrej Šitum, Ivan Martinez, Marko Popović, Luka Simetić, Dubravko Jalšovec

    Pulmonary sequestration (PS) is a congenital lung malformation, which is defined by an anomalous arterial supply from systemic circulation and an absence o

  • Open Access

    Benign Nodular Smooth Muscle Proliferation of the Lung Mimicking Malignancy

    by Tomislav Bečejac, Nikolina Tutić, Ana Mataić, Ivan Bunjevac

    We present an extremely rare and diagnostically challenging case of benign nodular smooth muscle proliferation (NSMP) in the lungs. A 41-year-old female patient presented with a cough and a right upper lung lobe lesion. Multislice computed tomography and positron emission tomography/computed tomography suggested malignancy despite relatively low metabolic activity. Fiberoptic bronchoscopy and transthoracic needle biopsy were inconclusive, so a right upper lobectomy with mediastinal lymphadenectomy was performed. Histopathology unveiled benign NSMP. This case underscores the diagnostic challenges of rare benign lung lesions mimicking malignancy and emphasizes a structured diagnostic and therapeutic approach. Clinical suspicion may arise in patients such as older adults presenting with well-defined pulmonary nodules, an inconclusive biopsy demonstrating smooth muscle proliferation, and low to moderate fluorodeoxyglucose uptake on positron emission tomography/computed tomography. When other diagnostic methods fail to provide a definitive diagnosis, surgical resection should be considered both as a diagnostic and therapeutic option. Histopathology remains the gold standard for differentiating benign from malignant lung lesions and enables definitive treatment in benign conditions, such as benign NSMP.

  • Esophagopericardial fistula: a late complication of liver stereotactic body radiation therapy

    by Katarina Sabol, Tomislav Bečejac, Pave Markoš, Nikolina Tutić, Larisa Čmelak, Ivan Martinez, Hrvoje Barić, Dubravko Jalšovec

    Esophagopericardial fistula (EPF) is an extremely rare, life-threatening condition that can develop following certain treatments. This case represents, to our knowledge, the first reported case of an EPF as a late complication of stereotactic body radiation therapy (SBRT) for liver metastases. It emphasizes the need for collaborative and individualized management strategies, particularly in the context of post-radiation tissue changes. A female patient in her late sixties, with a history of colon adenocarcinoma, previously treated with SBRT for liver metastases, presented with signs of cardiac tamponade. A multislice computed tomography (MSCT) scan confirmed EPF, and a multidisciplinary board was assembled to manage the patient. Initial management involved urgent pericardial drainage and vancomycin irrigation, followed by an endoscopic placement of a fully covered self-expandable esophageal metal stent. After the intervention, the patient’s clinical condition significantly improved. The stent remained in place and maintained a stable position during a 6-month follow-up period. Given the rarity and diverse etiologies of EPF, it is essential to manage each case individually, taking into account prior interventions and the patient’s healing capacities. Our experience highlights the importance of prompt hemodynamic stabilization, restoration of anatomical integrity, and a tailored approach to each patient. Specifically, permanent stent retention may be justified when radiation-impaired healing is present. Although EPF will remain uncommon, adherence to these principles, implemented through a multidisciplinary approach, can optimize outcomes when this severe complication does occur.

  • Open Access

    Tracheocutaneous Fistula Resolved by Pentadecapeptide BPC 157 Therapy Through the NO-System—Triple NO-Agent Approach in Rats

    by Goran Madzarac, Tomislav Becejac, Toni Penovic, Dominik Drazenovic, Lucija Kralj, Marta Popović Dolic, Suncana Sikiric, Lidija Beketic Oreskovic, Ivana Oreskovic, Sanja Strbe, et al.

    Background/Objectives: This 7-day rat tracheocutaneous fistula study considered the not-studied issues of tracheocutaneous fistula course, wound healing, and fistula in the NO-system relations. Therefore, we focused on fistulas’ severe course, tracheocutaneous fistula → air leak → compensatory diaphragmatic/abdominal “heaving”, NO-system failed relations, and therapy resolution. Stable gastric pentadecapeptide BPC 157 was proposed. Methods: Tracheocutaneous fistula rats received daily medication (/kg), alone or combined, BPC 157 therapy (10 µg, 10 ng, in drinking water or intraperitoneally) along with a triple NO-agent approach (L-NAME 5 mg, L-arginine 100 mg, and L-NAME+L-arginine, intraperitoneally). Results: Tracheocutaneous fistulas occurred as specific and NO-system-related as follows: NO system: blockade (L-NAME-aggravation) over-activity (L-arginine-amelioration) or immobilization (L-NAME+L-arginine oppose each other’s effects). Controls presented severe clinical signs of respiratory distress, failed healing, skin and tracheal defects, a not-healed and open, macro/microscopically, and fistulous tract that was well-formed and wide, tracheal shrinking below the fistula, and clinically, open-mouth breathing, “heaving abdomen”, cyanosis (bluish snout, ears, extremities), abundant secretion through the fistula, and weight loss. Fistula tissue NO level decreased, and the malondialdehyde (MDA) level increased. The BPC 157 therapy (both application routes) resulted in rapid recovery. Healing of defects (skin and trachea) and fistula closure, macro/microscopically, corresponded with clinical findings, avoiding observable clinical signs of dyspnea, reducing weight loss, and avoiding any sign of “heaving abdomen”. BPC 157-treated rats displayed regular breathing movements without observable signs of respiratory distress. Finally, when combined, BPC 157 therapy upgrades L-arginine amelioration, abolishes L-NAME-induced worsening, and restores full healing after NO immobilization (L-NAME+L-arginine). BPC 157 counteracted increase in NO level and counteracted increase in MDA level. Conclusions: Thus, first, acting systemically, BPC 157 reverses tracheocutaneous fistula course in rats. It acts through the NO system.


  • Open Access

    Acute Compartment Syndrome and Intra-Abdominal Hypertension, Decompression, Current Pharmacotherapy, and Stable Gastric Pentadecapeptide BPC 157 Solution

    by Predrag Sikiric, Sven Seiwerth, Anita Skrtic, Mario Staresinic, Sanja Strbe, Antonia Vuksic, Suncana Sikiric, Dinko Bekic, Toni Penovic, Dominik Drazenovic, et al.

    In this study, pharmacotherapies of abdominal compartment syndrome (ACS) and intra-abdominal hypertension (IAH) in animal studies were reviewed from the perspective of ACS/IAH as failed cytoprotection issues, as non-specific injuries, and from the point of view of the cytoprotection concept as resolution. Therefore, this review challenges the unresolved theoretical and practical issues of severe multiorgan failure, acknowledged significance in clinics, and resolving outcomes (i.e., open abdomen). Generally, the reported agents not aligned with cytoprotection align with current pharmacotherapy limitations and have (non-)confirmed effectiveness, mostly in only one organ, mild/moderate IAH, prophylactic application, and provide only a tentative resolution. Contrarily, stable gastric pentadecapeptide BPC 157 therapy, as a novel and relevant cytoprotective mediator having pleiotropic beneficial effects, simultaneously resolves many targets, resolving established disturbances, specifically compression/ischemia (grade III and grade IV), and decompression/advanced reperfusion. BPC 157 therapy rapidly activates collateral bypassing pathways, and, in ACS and IAH, and later, in reperfusion, there is a “bypassing key” (i.e., azygos vein direct blood flow delivery). This serves to counteract multiorgan and vessel failure, including lesions and hemorrhages in the brain, heart, lung, liver, kidney and gastrointestinal tract, thrombosis, peripherally and centrally, intracranial (superior sagittal sinus), portal and caval hypertension and aortal hypotension, occlusion/occlusion-like syndrome, advanced Virchow triad circumstances, and free radical formation acting as a membrane stabilizer and free radical scavenger. Likewise, not only in ACS/IAH resolving, but also in other occlusion/occlusion-like syndromes, this “bypassing key” could be an effect of the essential endothelial cytoprotective capacity of BPC 157 and a particular modulatory effect on the NO-system, and a rescuing impact on vasomotor tone.